Promoter hypermethylation of death-associated protein kinase gene in cholangiocarcinoma

Hepatobiliary and Pancreatic Diseases International

Volumn 6, Issue 4, 2007, Pages 407-411

  Liu, Xiao Fang ^a   Kong, Fan Min ^b   Xu, Zheng ^a   Yu, Shao Ping ^a   Sun, Fu Bo ^a   Zhang, Cui Sheng ^a   Huang, Qing Xian ^a   Zhou, Xian Ting ^a   Song, Zhan Wen ^a  

^a QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Cholangiocarcinoma; DAPK gene; Epigenetic alteration; Methylation specific PCR

Indexed keywords

CYTOSINE; DEATH ASSOCIATED PROTEIN KINASE; MESSENGER RNA; URACIL;

APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CANCER INVASION; CARCINOGENESIS; CLINICAL ARTICLE; CPG ISLAND; DNA METHYLATION; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; PAPILLARY CARCINOMA; PROMOTER REGION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE DIFFERENTIATION;

ADULT; AGED; APOPTOSIS REGULATORY PROTEINS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASES; CALMODULIN; CHOLANGIOCARCINOMA; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; PROMOTER REGIONS (GENETICS); SULFITES;

EID: 34548055951     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Gonzalez-Gomez P, Bello MJ, Arjona D, Alonso ME, Lomas J, De Campos JM, et al. Aberrant CpG island methylation in neurofibromas and neurofibrosarcomas. Oncol Rep 2003;10:1519-1523.
2. Bello MJ, Aminoso C, Lopez-Marin I, Arjona D, Gonzalez-Gomez P, Alonso ME, et al. DNA methylation of multiple promoter-associated CpG islands in meningiomas: relationship with the allelic status at lp and 22q. Acta Neuropathol (Berl) 2004;108:413-421.
3. Alonso ME, Bello MJ, Gonzalez-Gomez P, Arjona D, Lomas J, de Campos JM, et al. Aberrant promoter methylation of multiple genes in oligodendrogliomas and ependymomas. Cancer Genet Cytogenet 2003;144:134-142.
4. Jang CW, Chen CH, Chen CC, Chen JY, Su YH, Chen RH. TGF-beta induces apoptosis through Smad-mediated expression of DAP-kinase. Nat Cell Biol 2002;4:51-58.
5. Gao Y, Qian WP, Dark K, Toraldo G, Lin AS, Guldberg RE, et al. Estrogen prevents bone loss through transforming growth factor beta signaling in T cells. Proc Natl Acad Sci U S A 2004;101:16618-16623.
6. Mussig C, Altmann T. Genomic brassinosteroid effects. J Plant Growth Regul 2003;22:313-324.
7. Maruyama R, Toyooka S, Toyooka KO, Virmani AK, Zochbauer-Muller S, Farinas AJ, et al. Aberrant promoter methylation profile of prostate cancers and its relationship to dinicopathological features. Clin Cancer Res 2002;8: 514-519.
8. Belinsky SA, Palmisano WA, Gilliland FD, Crooks LA, Divine KK, Winters SA, et al. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res 2002;62:2370-2377.
9. Jeong DH, Youm MY, Kim YN, Lee KB, Sung MS, Yoon HK, et al. Promoter methylation of p16, DAPK, CDH1, and TIMP-3 genes in cervical cancer: correlation with clinicopathologic characteristics. Int J Gynecol Cancer 2006; 16:1234-1240.
10. Kong WJ, Zhang S, Guo CK, Wang YJ, Chen X, Zhang SL, et al. Effect of methylation-associated silencing of the death-associated protein kinase gene on nasopharyngeal carcinoma. Anticancer Drugs 2006;17:251-259.
11. Mittag F, Kuester D, Vieth M, Peters B, Stolte B, Roessner A, et al. DAPK promotor methylation is an early event in colorectal carcinogenesis. Cancer Lett 2006;240:69-75.
12. Friedrich MG, Chandrasoma S, Siegmund KD, Weisenberger DI, Cheng JC, Toma MI, et al. Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma. Eur J Cancer 2005;41: 2769-2778.
13. Safar AM, Spencer H 3rd, Su X, Coffey M, Cooney CA, Ratnasinghe LD, et al. Methylation profiling of archived non-small cell lung cancer: a promising prognostic system. Clin Cancer Res 2005;11:4400-4405.
14. Liu XF, Zhu SG, Zhang H, Xu Z, Su HL, Li SJ, et al. The methylation status of the TMS1/ASC gene in cholangiocarcinoma and its clinical significance. Hepatobiliary Pancreat Dis Int 2006;5:449-453.
15. Ohtsuka T, Liu XF, Koga Y, Kitajima Y, Nakafusa Y, Ha CW, et al. Methylation-induced silencing of ASC and the effect of expressed ASC on p53-mediated chemosensitivity in colorectal cancer. Oncogene 2006;25:1807-1811.
16. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet 2005;366:1303-1314.
17. Liu XF, Zhou XT, Zou SQ. An analysis of 680 cases of cholangiocarcinoma from 8 hospitals. Hepatobiliary Pancreat Dis Int 2005;4:585-588.
18. Malhi H, Gores GJ. Cholangiocarcinoma: modern advances in understanding a deadly old disease, J Hepatol 2006;45: 856-867.
19. Singh P, Patel T. Advances in the diagnosis, evaluation and management of cholangiocarcinoma. Curr Opin Gastroenterol 2006;22:294-299.
20. Hong SM, Choi J, Ryu K, Ro JY, Yu E. Promoter hypermethylation of the p16 gene and loss of its protein expression is correlated with tumor progression in extrahepatic bile duct carcinomas. Arch Pathol Lab Med 2006;130:33-38.
21. Foja S, Goldberg M, Schagdarsurengin U, Dammann R, Tannapfel A, Ballhausen WG. Promoter methylation and loss of coding exons of the fragile histidine triad (FHIT) gene in intrahepatic cholangiocarcinomas. Liver Int 2005; 25:1202-1208.
22. Limpaiboon T, Khaenam P, Chinnasri E, Soonklang M, Jearanaikoon P, Sripa B, et al. Promoter hypermethylation is a major event of hMLH1 gene inactivation in liver fluke related cholangiocarcinoma. Cancer Lett 2005;217:213-219.
23. Guo M, House MG, Hooker C, Han Y, Heath E, Gabrielson E, et al. Promoter hypermethylation of resected bronchial margins: a field defect of changes? Clin Cancer Res 2004;10:5131-5136.